St Jude flat in Q2 – but could have been worse
This article was originally published in Clinica
St Jude Medical saw flat sales during its second fiscal quarter, at $1.4 billion. Although not a great result, this was not as disastrous as analysts had predicted – they had expected a 4% drop in revenue, which would have marked a fifth consecutive quarter of year-on-year declines (www.clinica.co.uk, 16 July). St Jude’s Q2 earnings of $107 million fell short of the $244 million posted this time last year; but adjusted Q2 2013 net earnings were better, at $275 million or $0.96 per share, versus $276 million or $0.88 in Q2 2012.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.